Fig. 5

The micron-sized MCT adjuvant shows comparable activity to B type CpGs and is superior to Alum in driving protection against B16F10p33 melanoma. a vaccination scheme for four vaccine groups, CuMV_TT-VLPs, CuMV_TT-p33 admixed with CpG 1668, CuMV_TT-p33 formulated with MCT and CuMV_TT-p33 formulated with Alum. b Tumour growth curve of subcutaneous B16F10p33 melanomas in each vaccinated group, mice were euthanized when the tumour reached ~1000mm³, arrows indicate start of treatment. c Representative flow cytometry dot plots showing the total number of CD8⁺ T cells in each vaccinated group, gated on TILs. d Representative flow cytometry dot plots showing the total number of CD8⁺ Tetramer⁺ CTLs in each vaccinated group, gated on CD8⁺ T cells. e Density of CD8⁺ T cells (means ± SEM) in each vaccinated group, “measured by dividing the total number of CD8⁺ cells in TILs by the tumour volume^”. f Density of CD8⁺ Tetramer⁺ CTLs (means ± SEM) in each vaccinated group, “measured by dividing the total number of p33 tetramer⁺ CTLs by tumour volume^”. Statistical analysis by Student’s t test. (4 mice per group), one representative of 3 similar experiments is shown